nach oben

Current Oncology Reports

Erschienen in:

01.12.2020 | Lung Cancer (H Borghaei, Section Editor)

Combined Inhibition of EGFR and VEGF Pathways in Patients with EGFR-Mutated Non-Small Cell Lung Cancer: A Systematic Review and Meta-Analysis

verfasst von: Monica Peravali, Haijun Wang, Chul Kim, Irina Veytsman

Erschienen in: Current Oncology Reports | Ausgabe 12/2020

Einloggen, um Zugang zu erhalten

Abstract

Purpose of Review

Dual inhibition of epidermal growth factor receptor (EGFR) and vascular endothelial growth factor (VEGF) pathways could potentiate improved outcomes in patients with metastatic EGFR-mutated non-small cell lung cancer (NSCLC). The purpose of this systematic review and meta-analysis was to compare the efficacy of an EGFR tyrosine kinase inhibitor (TKI) plus a VEGF inhibitor with EGFR TKI alone for the treatment of EGFR-mutated NSCLC.

Recent Findings

We systematically searched for randomized controlled trials (RCT) that involved patients with EGFR-mutated metastatic NSCLC treated with combination therapy versus EGFR TKI alone. In a pooled analysis of 5 studies, treatment with the combination therapy was associated with statistically significant improvements in progression-free survival (hazard ratio [HR] 0.63, 95% CI [0.54, 0.75]) when compared with control. However, pooled data from 4 studies revealed no statistically significant differences between the 2 groups for overall survival (HR 1.00, 95% CI [0.68, 1.52]) and the objective response rate (relative risk [RR] 1.05, 95% CI [0.97, 1.14]).

Summary

In patients with metastatic EGFR-mutated NSCLC, treatment with EGFR TKI plus VEGF inhibition provided significant improvements in progression-free survival, but not in overall survival or objective response rate, when compared with treatment with EGFR TKI alone.

American Cancer Society. Cancer Facts & Figures 2019. Atlanta: American Cancer Society; 2019.

Mok TS, Wu Y-L, Thongprasert S, Yang C-H, Chu D-T, Saijo N, et al. Gefitinib or carboplatin–paclitaxel in pulmonary adenocarcinoma. N Engl J Med. 2009;361(10):947–57. https://doi.org/10.1056/NEJMoa0810699.CrossRefPubMed

Rosell R, Carcereny E, Gervais R, Vergnenegre A, Massuti B, Felip E, et al. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol. 2012;13(3):239–46. https://doi.org/10.1016/s1470-2045(11)70393-x.CrossRefPubMed

Wu YL, Zhou C, Hu CP, Feng J, Lu S, Huang Y, et al. Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial. Lancet Oncol. 2014;15(2):213–22. https://doi.org/10.1016/s1470-2045(13)70604-1.CrossRefPubMed

Mok TS, Cheng Y, Zhou X, Lee KH, Nakagawa K, Niho S, et al. Improvement in overall survival in a randomized study that compared dacomitinib with gefitinib in patients with advanced non–small-cell lung cancer and EGFR-activating mutations. J Clin Oncol. 2018;36(22):2244–50. https://doi.org/10.1200/jco.2018.78.7994.CrossRefPubMed

Mok TS, Wu Y-L, Ahn M-J, Garassino MC, Kim HR, Ramalingam SS, et al. Osimertinib or platinum–pemetrexed in EGFR T790M–positive lung cancer. N Engl J Med. 2016;376(7):629–40. https://doi.org/10.1056/NEJMoa1612674.CrossRefPubMedPubMedCentral

Hung MS, Chen IC, Lin PY, Lung JH, Li YC, Lin YC, et al. Epidermal growth factor receptor mutation enhances expression of vascular endothelial growth factor in lung cancer. Oncol Lett. 2016;12(6):4598–604. https://doi.org/10.3892/ol.2016.5287.CrossRefPubMedPubMedCentral

Sandler A, Gray R, Perry MC, Brahmer J, Schiller JH, Dowlati A, et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med. 2006;355(24):2542–50. https://doi.org/10.1056/NEJMoa061884.CrossRefPubMed

Soria JC, Mauguen A, Reck M, Sandler AB, Saijo N, Johnson DH, et al. Systematic review and meta-analysis of randomised, phase II/III trials adding bevacizumab to platinum-based chemotherapy as first-line treatment in patients with advanced non-small-cell lung cancer. Ann Oncol. 2013;24(1):20–30. https://doi.org/10.1093/annonc/mds590.CrossRefPubMed

10.

Garon EB, Ciuleanu TE, Arrieta O, Prabhash K, Syrigos KN, Goksel T, et al. Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial. Lancet. 2014;384(9944):665–73. https://doi.org/10.1016/s0140-6736(14)60845-x.CrossRefPubMed

11.

Byers LA, Heymach JV. Dual targeting of the vascular endothelial growth factor and epidermal growth factor receptor pathways: rationale and clinical applications for non-small-cell lung cancer. Clin Lung Cancer. 2007;8(Suppl 2):S79–85. https://doi.org/10.3816/clc.2007.s.006.CrossRefPubMed

12.

Takeuchi S, Wang W, Li Q, Yamada T, Kita K, Donev IS, et al. Dual inhibition of Met kinase and angiogenesis to overcome HGF-induced EGFR-TKI resistance in EGFR mutant lung cancer. Am J Pathol. 2012;181(3):1034–43. https://doi.org/10.1016/j.ajpath.2012.05.023.CrossRefPubMed

13.

Naumov GN, Nilsson MB, Cascone T, Briggs A, Straume O, Akslen LA, et al. Combined vascular endothelial growth factor receptor and epidermal growth factor receptor (EGFR) blockade inhibits tumor growth in xenograft models of EGFR inhibitor resistance. Clin Cancer Res. 2009;15(10):3484–94. https://doi.org/10.1158/1078-0432.Ccr-08-2904.CrossRefPubMedPubMedCentral

14.

Dingemans AM, de Langen AJ, van den Boogaart V, Marcus JT, Backes WH, Scholtens HT, et al. First-line erlotinib and bevacizumab in patients with locally advanced and/or metastatic non-small-cell lung cancer: a phase II study including molecular imaging. Ann Oncol. 2011;22(3):559–66. https://doi.org/10.1093/annonc/mdq391.CrossRefPubMed

15.

Herbst RS, Ansari R, Bustin F, Flynn P, Hart L, Otterson GA, et al. Efficacy of bevacizumab plus erlotinib versus erlotinib alone in advanced non-small-cell lung cancer after failure of standard first-line chemotherapy (BeTa): a double-blind, placebo-controlled, phase 3 trial. Lancet. 2011;377(9780):1846–54. https://doi.org/10.1016/s0140-6736(11)60545-x.CrossRefPubMedPubMedCentral

16.

•• Nakagawa K, Garon EB, Seto T, Nishio M, Ponce Aix S, Paz-Ares L, et al. Ramucirumab plus erlotinib in patients with untreated, EGFR-mutated, advanced non-small-cell lung cancer (RELAY): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2019;20(12):1655–69. https://doi.org/10.1016/s1470-2045(19)30634-5To date, this is the largest randomized phase III study comparing 1^st generation EGFR TKI, erlotinib, with VEGF monoclonal antibody, ramucirumab, as front-line therapy in stage IV EGFR-mutated NSCLC. Results showed improved PFS in the combination arm; however, the OS data is still immature and can potentially add valuable insight into the superior efficacy of the combination.CrossRefPubMed

17.

•• Saito H, Fukuhara T, Furuya N, Watanabe K, Sugawara S, Iwasawa S, et al. Erlotinib plus bevacizumab versus erlotinib alone in patients with EGFR-positive advanced non-squamous non-small-cell lung cancer (NEJ026): interim analysis of an open-label, randomised, multicentre, phase 3 trial. Lancet Oncol. 2019;20(5):625–35. https://doi.org/10.1016/s1470-2045(19)30035-xThis interim analysis of a phase III trial comparing treatment with erlotinib plus a VEGF inhibitior, bevacizumab, versus erlotinib alone found that combination treatment resulted in superior PFS compared to control. The OS data is still immature.CrossRefPubMed

18.

Scagliotti GV, Krzakowski M, Szczesna A, Strausz J, Makhson A, Reck M, et al. Sunitinib plus erlotinib versus placebo plus erlotinib in patients with previously treated advanced non-small-cell lung cancer: a phase III trial. J Clin Oncol. 2012;30(17):2070–8. https://doi.org/10.1200/jco.2011.39.2993.CrossRefPubMed

19.

Seto T, Kato T, Nishio M, Goto K, Atagi S, Hosomi Y, et al. Erlotinib alone or with bevacizumab as first-line therapy in patients with advanced non-squamous non-small-cell lung cancer harbouring EGFR mutations (JO25567): an open-label, randomised, multicentre, phase 2 study. Lancet Oncol. 2014;15(11):1236–44. https://doi.org/10.1016/s1470-2045(14)70381-x.CrossRefPubMed

20.

Stinchcombe TE, Janne PA, Wang X, Bertino EM, Weiss J, Bazhenova L, et al. Effect of Erlotinib plus bevacizumab vs erlotinib alone on progression-free survival in patients with advanced EGFR-mutant non-small cell lung cancer: a phase 2 randomized clinical trial. JAMA Oncol. 2019;5:1448. https://doi.org/10.1001/jamaoncol.2019.1847.CrossRefPubMedCentralPubMed

21.

• Yamamoto N, Seto T, Nishio M, Goto K, Okamoto I, Yamanaka T, et al. Erlotinib plus bevacizumab (EB) versus erlotinib alone (E) as first-line treatment for advanced EGFR mutation–positive non-squamous non–small-cell lung cancer (NSCLC): survival follow-up results of JO25567. J Clin Oncol. 2018;36(15_suppl):9007. https://doi.org/10.1200/JCO.2018.36.15_suppl.9007This ASCO abstract reported updated OS data from the original JO25567 study (a phase II randomized trial of erlotinib plus bevacizumab versus erlotinib alone) and found no significant difference in OS. An improved PFS was reported earlier by Seto et al however did not translate to OS benefit.CrossRef

22.

Hata A, Katakami N, Kaji R, Yokoyama T, Kaneda T, Tamiya M, et al. Afatinib plus bevacizumab combination after acquired resistance to EGFR tyrosine kinase inhibitors in EGFR-mutant non-small cell lung cancer: multicenter, single-arm, phase 2 trial (ABC study). Cancer. 2018;124(19):3830–8. https://doi.org/10.1002/cncr.31678.CrossRefPubMed

23.

Ichihara E, Hotta K, Nogami N, Kuyama S, Kishino D, Fujii M, et al. Phase II trial of gefitinib in combination with bevacizumab as first-line therapy for advanced non-small cell lung cancer with activating EGFR gene mutations: the Okayama lung cancer study group trial 1001. J Thorac Oncol. 2015;10(3):486–91. https://doi.org/10.1097/jto.0000000000000434.CrossRefPubMed

24.

Reckamp KL, Frankel PH, Ruel N, Mack PC, Gitlitz BJ, Li T, et al. Phase II trial of cabozantinib plus erlotinib in patients with advanced epidermal growth factor receptor (EGFR)-mutant non-small cell lung cancer with progressive disease on epidermal growth factor receptor tyrosine kinase inhibitor therapy: a California cancer consortium phase II trial (NCI 9303). Front Oncol. 2019;9:132. https://doi.org/10.3389/fonc.2019.00132.CrossRefPubMedPubMedCentral

25.

Zappa F, Droege C, Betticher D, von Moos R, Bubendorf L, Ochsenbein A, et al. Bevacizumab and erlotinib (BE) first-line therapy in advanced non-squamous non-small-cell lung cancer (NSCLC) (stage IIIB/IV) followed by platinum-based chemotherapy (CT) at disease progression: a multicenter phase II trial (SAKK 19/05). Lung Cancer. 2012;78(3):239–44. https://doi.org/10.1016/j.lungcan.2012.08.017.CrossRefPubMed

26.

Rosell R, Dafni U, Felip E, Curioni-Fontecedro A, Gautschi O, Peters S, et al. Erlotinib and bevacizumab in patients with advanced non-small-cell lung cancer and activating EGFR mutations (BELIEF): an international, multicentre, single-arm, phase 2 trial. Lancet Respir Med. 2017;5(5):435–44. https://doi.org/10.1016/s2213-2600(17)30129-7.CrossRefPubMed

27.

Zhang TT, Wang RM, Yang Z, Chen GB. Dual inhibiting EGFR and VEGF pathways versus EGFR-TKIs alone in the treatment of advanced non-small-cell lung cancer: a meta-analysis of randomized controlled trials. Clin Transl Oncol. 2016;18(6):576–81. https://doi.org/10.1007/s12094-015-1402-z.CrossRefPubMed

28.

Soria J-C, Ohe Y, Vansteenkiste J, Reungwetwattana T, Chewaskulyong B, Lee KH, et al. Osimertinib in untreated EGFR-mutated advanced non–small-cell lung cancer. N Engl J Med. 2017;378(2):113–25. https://doi.org/10.1056/NEJMoa1713137.CrossRefPubMed

29.

Ramalingam SS, Vansteenkiste J, Planchard D, Cho BC, Gray JE, Ohe Y, et al. Overall survival with osimertinib in untreated, EGFR-mutated advanced NSCLC. N Engl J Med. 2020;382(1):41–50. https://doi.org/10.1056/NEJMoa1913662.CrossRefPubMed

Titel: Combined Inhibition of EGFR and VEGF Pathways in Patients with EGFR-Mutated Non-Small Cell Lung Cancer: A Systematic Review and Meta-Analysis
verfasst von: Monica Peravali
Haijun Wang
Chul Kim
Irina Veytsman
Publikationsdatum: 01.12.2020
Verlag: Springer US
Erschienen in: Current Oncology Reports / Ausgabe 12/2020
Print ISSN: 1523-3790
Elektronische ISSN: 1534-6269
DOI: https://doi.org/10.1007/s11912-020-00981-0

Die Highlights vom Kongress des American College of Cardiology 2024

Springer Medizin

Combined Inhibition of EGFR and VEGF Pathways in Patients with EGFR-Mutated Non-Small Cell Lung Cancer: A Systematic Review and Meta-Analysis

Abstract

Purpose of Review

Recent Findings

Summary

Neu im Fachgebiet Onkologie

Alphablocker schützt vor Miktionsproblemen nach der Biopsie

Antikörper-Wirkstoff-Konjugat hält solide Tumoren in Schach

Mammakarzinom: Senken Statine das krebsbedingte Sterberisiko?

Labor, CT-Anthropometrie zeigen Risiko für Pankreaskrebs

Update Onkologie

Die Highlights vom Kongress des American College of Cardiology 2024

Springer Medizin

Abstract

Purpose of Review

Recent Findings

Summary

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 12/2020

Access to Therapy for Acute Myeloid Leukemia in the Developing World: Barriers and Solutions

Alternative Checkpoints as Targets for Immunotherapy

The Value of Virtual Chromoendoscopy in the Workup of Patients with Head and Neck Squamous Cell Carcinoma

Isocitrate Dehydrogenase, Patient-Reported Outcomes, and Cognitive Functioning of Glioma Patients: a Systematic Review

Extended Endocrine Therapy for Early-Stage Breast Cancer: How Do We Decide?

Multidisciplinary Outpatient Cancer Rehabilitation Can Improve Cancer Patients’ Physical and Psychosocial Status—a Systematic Review

Neu im Fachgebiet Onkologie

Alphablocker schützt vor Miktionsproblemen nach der Biopsie

Antikörper-Wirkstoff-Konjugat hält solide Tumoren in Schach

Mammakarzinom: Senken Statine das krebsbedingte Sterberisiko?

Labor, CT-Anthropometrie zeigen Risiko für Pankreaskrebs

Update Onkologie